Clinical Trial Update: A Pilot Study of Recombinant Human Arginase 1 (rhArg1) in Patients With Relapsed or Refractory Leukemia or Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial of Recombinant Human Arginase 1 (rhArg1) in relapsed or refractory leukemia or lymphoma has been terminated. This status update indicates the stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma

Drugs mentioned

• Recombinant Human Arginase 1 (recombinant human arginase 1)

Snippet

Sponsor: Bio-Cancer Treatment International Limited | Conditions: Leukemia, Lymphoma | Phase 1 | Status: TERMINATED